pmc-enju-pas Home  

PMC:3586680 / 1137-2220 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T910 0-12 NN denotes Glioblastoma
T911 13-23 JJ denotes multiforme
T912 24-32 NN denotes afflicts
T913 33-39 CD denotes 12,500
T914 40-43 JJ denotes new
T915 44-52 NN denotes patients
T916 53-55 IN denotes in
T917 56-59 DT denotes the
T918 60-64 NNP denotes U.S.
T919 65-73 RB denotes annually
T920 74-75 -LRB- denotes (
T921 75-83 NNP denotes Friedman
T922 84-86 FW denotes et
T923 87-90 FW denotes al.
T924 90-91 -COMMA- denotes ,
T925 92-96 CD denotes 2000
T926 96-97 -COLON- denotes ;
T927 98-103 NNP denotes Stupp
T928 104-106 FW denotes et
T929 107-110 FW denotes al.
T930 110-111 -COMMA- denotes ,
T931 112-116 CD denotes 2009
T932 116-117 -COLON- denotes ;
T933 118-124 NNP denotes Silber
T934 125-127 FW denotes et
T935 128-131 FW denotes al.
T936 131-132 -COMMA- denotes ,
T937 133-137 CD denotes 2012
T938 137-138 -RRB- denotes )
T939 140-152 NN denotes Glioblastoma
T940 153-154 -LRB- denotes (
T941 154-157 NN denotes GBM
T942 157-158 -RRB- denotes )
T943 159-161 VB denotes is
T944 162-168 RB denotes highly
T945 169-175 JJ denotes lethal
T946 175-176 -COMMA- denotes ,
T947 177-180 CC denotes and
T948 181-184 DT denotes the
T949 185-192 JJ denotes average
T950 193-201 NN denotes survival
T951 202-212 NN denotes expectancy
T952 213-215 VB denotes is
T953 216-227 NN denotes 14.6 months
T954 227-228 -COMMA- denotes ,
T955 229-232 CC denotes and
T956 233-236 DT denotes the
T957 237-244 JJ denotes overall
T958 245-251 JJ denotes 5-year
T959 252-260 NN denotes survival
T960 261-265 NN denotes rate
T961 266-269 IN denotes for
T962 270-273 NN denotes GBM
T963 274-276 VB denotes is
T964 277-281 RB denotes only
T965 282-285 CD denotes 9.8
T966 285-286 NN denotes %
T967 287-288 -LRB- denotes (
T968 288-296 NNP denotes Friedman
T969 297-299 FW denotes et
T970 300-303 FW denotes al.
T971 303-304 -COMMA- denotes ,
T972 305-309 CD denotes 2000
T973 309-310 -COLON- denotes ;
T974 311-316 NNP denotes Stupp
T975 317-319 FW denotes et
T976 320-323 FW denotes al.
T977 323-324 -COMMA- denotes ,
T978 325-329 CD denotes 2009
T979 329-330 -RRB- denotes )
T980 332-336 JJ denotes High
T981 337-343 NN denotes levels
T982 344-346 IN denotes of
T983 347-357 NN denotes resistance
T984 358-360 TO denotes to
T985 361-368 JJ denotes current
T986 369-380 JJ denotes therapeutic
T987 381-391 NN denotes modalities
T988 392-395 CC denotes and
T989 396-402 NN denotes cancer
T990 403-410 NN denotes relapse
T991 411-414 VB denotes are
T992 415-425 RB denotes frequently
T993 426-430 VB denotes seen
T994 431-433 IN denotes in
T995 434-442 NN denotes patients
T996 443-444 -LRB- denotes (
T997 444-448 NNP denotes Haar
T998 449-451 FW denotes et
T999 452-455 FW denotes al.
T1000 455-456 -COMMA- denotes ,
T1001 457-461 CD denotes 2012
T1002 461-462 -COLON- denotes ;
T1003 463-470 NNP denotes Happold
T1004 471-473 FW denotes et
T1005 474-477 FW denotes al.
T1006 477-478 -COMMA- denotes ,
T1007 479-483 CD denotes 2012
T1008 483-484 -RRB- denotes )
T1009 486-489 DT denotes The
T1010 490-497 JJ denotes current
T1011 498-506 JJ denotes standard
T1012 507-514 NN denotes therapy
T1013 515-518 IN denotes for
T1014 519-522 NN denotes GBM
T1015 523-529 RB denotes mainly
T1016 530-538 VB denotes includes
T1017 539-546 JJ denotes maximum
T1018 547-556 VB denotes debulking
T1019 557-564 NN denotes surgery
T1020 564-565 -COMMA- denotes ,
T1021 566-575 NN denotes radiation
T1022 575-576 -COMMA- denotes ,
T1023 577-580 CC denotes and
T1024 581-590 NN denotes treatment
T1025 591-595 IN denotes with
T1026 596-599 DT denotes the
T1027 600-614 JJ denotes monofunctional
T1028 615-625 VB denotes alkylating
T1029 626-631 NN denotes agent
T1030 632-644 NN denotes temozolomide
T1031 645-646 -LRB- denotes (
T1032 646-649 NN denotes TMZ
T1033 649-650 -RRB- denotes )
T1034 651-652 -LRB- denotes (
T1035 652-660 NNP denotes Friedman
T1036 661-663 FW denotes et
T1037 664-667 FW denotes al.
T1038 667-668 -COMMA- denotes ,
T1039 669-673 CD denotes 2000
T1040 673-674 -COLON- denotes ;
T1041 675-684 NNP denotes Nishikawa
T1042 684-685 -COMMA- denotes ,
T1043 686-690 CD denotes 2010
T1044 690-691 -RRB- denotes )
T1045 693-701 JJ denotes Multiple
T1046 702-712 NN denotes mechanisms
T1047 713-716 VB denotes are
T1048 717-725 VB denotes involved
T1049 726-728 IN denotes in
T1050 729-732 DT denotes the
T1051 733-736 NN denotes TMZ
T1052 737-747 NN denotes resistance
T1053 747-748 -COMMA- denotes ,
T1054 749-754 WDT denotes which
T1055 755-758 MD denotes may
T1056 759-766 VB denotes include
T1057 767-773 NN denotes cancer
T1058 774-778 NN denotes stem
T1059 779-784 NN denotes cells
T1060 784-785 -COMMA- denotes ,
T1061 786-795 NN denotes microRNAs
T1062 795-796 -COMMA- denotes ,
T1063 797-801 NN denotes drug
T1064 802-808 NN denotes efflux
T1065 808-809 -COMMA- denotes ,
T1066 810-813 NN denotes DNA
T1067 814-820 NN denotes damage
T1068 821-827 NN denotes repair
T1069 827-828 -COMMA- denotes ,
T1070 829-834 NN denotes tumor
T1071 835-840 NN denotes cells
T1072 841-846 IN denotes under
T1073 847-854 NN denotes hypoxia
T1074 854-855 -COMMA- denotes ,
T1075 856-863 NN denotes histone
T1076 864-877 NN denotes deacetylation
T1077 877-878 -COMMA- denotes ,
T1078 879-901 JJ denotes epithelial-mesenchymal
T1079 902-912 NN denotes transition
T1080 912-913 -COMMA- denotes ,
T1081 914-919 NN denotes STAT3
T1082 920-926 NN denotes kinase
T1083 926-927 -COMMA- denotes ,
T1084 928-931 CC denotes and
T1085 932-936 JJ denotes many
T1086 937-943 NN denotes others
T1087 944-945 -LRB- denotes (
T1088 945-949 NNP denotes Haar
T1089 950-952 FW denotes et
T1090 953-956 FW denotes al.
T1091 956-957 -COMMA- denotes ,
T1092 958-962 CD denotes 2012
T1093 962-963 -COLON- denotes ;
T1094 964-971 NNP denotes Happold
T1095 972-974 FW denotes et
T1096 975-978 FW denotes al.
T1097 978-979 -COMMA- denotes ,
T1098 980-984 CD denotes 2012
T1099 984-985 -COLON- denotes ;
T1100 986-997 NNP denotes Johannessen
T1101 998-1001 CC denotes and
T1102 1002-1010 NNP denotes Bjerkvig
T1103 1010-1011 -COMMA- denotes ,
T1104 1012-1016 CD denotes 2012
T1105 1016-1017 -COLON- denotes ;
T1106 1018-1025 NNP denotes Kitange
T1107 1026-1028 FW denotes et
T1108 1029-1032 FW denotes al.
T1109 1032-1033 -COMMA- denotes ,
T1110 1034-1038 CD denotes 2012
T1111 1038-1039 -COLON- denotes ;
T1112 1040-1047 NNP denotes Kohsaka
T1113 1048-1050 FW denotes et
T1114 1051-1054 FW denotes al.
T1115 1054-1055 -COMMA- denotes ,
T1116 1056-1060 CD denotes 2012
T1117 1060-1061 -COLON- denotes ;
T1118 1062-1067 NNP denotes Zhang
T1119 1068-1070 FW denotes et
T1120 1071-1074 FW denotes al.
T1121 1074-1075 -COMMA- denotes ,
T1122 1076-1081 NN denotes 2012b
T1123 1081-1082 -RRB- denotes )
R464 T915 T910 arg1Of patients,Glioblastoma
R465 T915 T911 arg1Of patients,multiforme
R466 T915 T912 arg1Of patients,afflicts
R467 T915 T913 arg1Of patients,"12,500"
R468 T915 T914 arg1Of patients,new
R469 T915 T916 arg1Of patients,in
R470 T915 T919 arg1Of patients,annually
R471 T915 T920 arg1Of patients,(
R472 T918 T916 arg2Of U.S.,in
R473 T918 T917 arg1Of U.S.,the
R474 T921 T920 arg2Of Friedman,(
R475 T921 T922 arg1Of Friedman,et
R476 T921 T923 arg1Of Friedman,al.
R477 T921 T924 arg1Of Friedman,","
R478 T921 T926 arg1Of Friedman,;
R479 T921 T932 arg1Of Friedman,;
R480 T925 T924 arg2Of 2000,","
R481 T927 T926 arg2Of Stupp,;
R482 T927 T928 arg1Of Stupp,et
R483 T927 T929 arg1Of Stupp,al.
R484 T927 T930 arg1Of Stupp,","
R485 T931 T930 arg2Of 2009,","
R486 T933 T932 arg2Of Silber,;
R487 T933 T934 arg1Of Silber,et
R488 T933 T935 arg1Of Silber,al.
R489 T933 T936 arg1Of Silber,","
R490 T937 T936 arg2Of 2012,","
R491 T938 T920 arg3Of ),(
R492 T939 T940 arg1Of Glioblastoma,(
R493 T939 T943 arg1Of Glioblastoma,is
R494 T939 T945 arg1Of Glioblastoma,lethal
R495 T941 T940 arg2Of GBM,(
R496 T942 T940 arg3Of ),(
R497 T943 T947 arg1Of is,and
R498 T945 T943 arg2Of lethal,is
R499 T945 T944 arg1Of lethal,highly
R500 T947 T946 arg1Of and,","
R501 T947 T955 arg1Of and,and
R502 T951 T948 arg1Of expectancy,the
R503 T951 T949 arg1Of expectancy,average
R504 T951 T950 arg1Of expectancy,survival
R505 T951 T952 arg1Of expectancy,is
R506 T951 T953 arg1Of expectancy,14.6 months
R507 T952 T947 arg2Of is,and
R508 T953 T952 arg2Of 14.6 months,is
R509 T955 T954 arg1Of and,","
R510 T960 T956 arg1Of rate,the
R511 T960 T957 arg1Of rate,overall
R512 T960 T958 arg1Of rate,5-year
R513 T960 T959 arg1Of rate,survival
R514 T960 T961 arg1Of rate,for
R515 T960 T963 arg1Of rate,is
R516 T962 T961 arg2Of GBM,for
R517 T963 T955 arg2Of is,and
R518 T963 T967 arg1Of is,(
R519 T965 T964 arg1Of 9.8,only
R520 T966 T963 arg2Of %,is
R521 T966 T965 arg1Of %,9.8
R522 T968 T967 arg2Of Friedman,(
R523 T968 T969 arg1Of Friedman,et
R524 T968 T970 arg1Of Friedman,al.
R525 T968 T971 arg1Of Friedman,","
R526 T968 T973 arg1Of Friedman,;
R527 T972 T971 arg2Of 2000,","
R528 T974 T973 arg2Of Stupp,;
R529 T974 T975 arg1Of Stupp,et
R530 T974 T976 arg1Of Stupp,al.
R531 T974 T977 arg1Of Stupp,","
R532 T978 T977 arg2Of 2009,","
R533 T979 T967 arg3Of ),(
R534 T981 T980 arg1Of levels,High
R535 T981 T982 arg1Of levels,of
R536 T981 T991 arg1Of levels,are
R537 T981 T993 arg2Of levels,seen
R538 T983 T984 arg1Of resistance,to
R539 T983 T988 arg1Of resistance,and
R540 T987 T984 arg2Of modalities,to
R541 T987 T985 arg1Of modalities,current
R542 T987 T986 arg1Of modalities,therapeutic
R543 T988 T982 arg2Of and,of
R544 T990 T988 arg2Of relapse,and
R545 T990 T989 arg1Of relapse,cancer
R546 T993 T991 arg2Of seen,are
R547 T993 T992 arg1Of seen,frequently
R548 T993 T994 arg1Of seen,in
R549 T993 T996 arg1Of seen,(
R550 T995 T994 arg2Of patients,in
R551 T997 T996 arg2Of Haar,(
R552 T997 T998 arg1Of Haar,et
R553 T997 T999 arg1Of Haar,al.
R554 T997 T1000 arg1Of Haar,","
R555 T997 T1002 arg1Of Haar,;
R556 T1001 T1000 arg2Of 2012,","
R557 T1003 T1002 arg2Of Happold,;
R558 T1003 T1004 arg1Of Happold,et
R559 T1003 T1005 arg1Of Happold,al.
R560 T1003 T1006 arg1Of Happold,","
R561 T1007 T1006 arg2Of 2012,","
R562 T1008 T996 arg3Of ),(
R563 T1012 T1010 arg1Of therapy,current
R564 T1012 T1011 arg1Of therapy,standard
R565 T1012 T1013 arg1Of therapy,for
R566 T1012 T1016 arg1Of therapy,includes
R567 T1012 T1009 arg1Of therapy,The
R568 T1014 T1013 arg2Of GBM,for
R569 T1016 T1015 arg1Of includes,mainly
R570 T1019 T1017 arg1Of surgery,maximum
R571 T1019 T1018 arg1Of surgery,debulking
R572 T1019 T1020 arg1Of surgery,","
R573 T1020 T1023 arg1Of ",",and
R574 T1021 T1020 arg2Of radiation,","
R575 T1023 T1016 arg2Of and,includes
R576 T1023 T1022 arg1Of and,","
R577 T1024 T1023 arg2Of treatment,and
R578 T1024 T1025 arg1Of treatment,with
R579 T1030 T1025 arg2Of temozolomide,with
R580 T1030 T1026 arg1Of temozolomide,the
R581 T1030 T1027 arg1Of temozolomide,monofunctional
R582 T1030 T1028 arg1Of temozolomide,alkylating
R583 T1030 T1029 arg1Of temozolomide,agent
R584 T1030 T1031 arg1Of temozolomide,(
R585 T1030 T1034 arg1Of temozolomide,(
R586 T1032 T1031 arg2Of TMZ,(
R587 T1033 T1031 arg3Of ),(
R588 T1035 T1034 arg2Of Friedman,(
R589 T1035 T1036 arg1Of Friedman,et
R590 T1035 T1037 arg1Of Friedman,al.
R591 T1035 T1038 arg1Of Friedman,","
R592 T1035 T1040 arg1Of Friedman,;
R593 T1039 T1038 arg2Of 2000,","
R594 T1041 T1040 arg2Of Nishikawa,;
R595 T1041 T1042 arg1Of Nishikawa,","
R596 T1043 T1042 arg2Of 2010,","
R597 T1044 T1034 arg3Of ),(
R598 T1046 T1045 arg1Of mechanisms,Multiple
R599 T1046 T1047 arg1Of mechanisms,are
R600 T1046 T1048 arg2Of mechanisms,involved
R601 T1048 T1047 arg2Of involved,are
R602 T1048 T1049 arg1Of involved,in
R603 T1052 T1049 arg2Of resistance,in
R604 T1052 T1050 arg1Of resistance,the
R605 T1052 T1051 arg1Of resistance,TMZ
R606 T1052 T1053 arg1Of resistance,","
R607 T1052 T1054 arg1Of resistance,which
R608 T1052 T1055 arg1Of resistance,may
R609 T1052 T1056 arg1Of resistance,include
R610 T1056 T1055 arg2Of include,may
R611 T1059 T1057 arg1Of cells,cancer
R612 T1059 T1058 arg1Of cells,stem
R613 T1059 T1060 arg1Of cells,","
R614 T1060 T1062 arg1Of ",",","
R615 T1061 T1060 arg2Of microRNAs,","
R616 T1062 T1065 arg1Of ",",","
R617 T1064 T1062 arg2Of efflux,","
R618 T1064 T1063 arg1Of efflux,drug
R619 T1065 T1069 arg1Of ",",","
R620 T1068 T1065 arg2Of repair,","
R621 T1068 T1066 arg1Of repair,DNA
R622 T1068 T1067 arg1Of repair,damage
R623 T1069 T1056 arg2Of ",",include
R624 T1069 T1072 arg1Of ",",under
R625 T1071 T1069 arg2Of cells,","
R626 T1071 T1070 arg1Of cells,tumor
R627 T1073 T1074 arg1Of hypoxia,","
R628 T1074 T1077 arg1Of ",",","
R629 T1076 T1074 arg2Of deacetylation,","
R630 T1076 T1075 arg1Of deacetylation,histone
R631 T1077 T1080 arg1Of ",",","
R632 T1079 T1077 arg2Of transition,","
R633 T1079 T1078 arg1Of transition,epithelial-mesenchymal
R634 T1080 T1084 arg1Of ",",and
R635 T1082 T1080 arg2Of kinase,","
R636 T1082 T1081 arg1Of kinase,STAT3
R637 T1084 T1072 arg2Of and,under
R638 T1084 T1083 arg1Of and,","
R639 T1086 T1084 arg2Of others,and
R640 T1086 T1085 arg1Of others,many
R641 T1086 T1087 arg1Of others,(
R642 T1088 T1087 arg2Of Haar,(
R643 T1088 T1089 arg1Of Haar,et
R644 T1088 T1090 arg1Of Haar,al.
R645 T1088 T1091 arg1Of Haar,","
R646 T1088 T1093 arg1Of Haar,;
R647 T1088 T1099 arg1Of Haar,;
R648 T1092 T1091 arg2Of 2012,","
R649 T1094 T1093 arg2Of Happold,;
R650 T1094 T1095 arg1Of Happold,et
R651 T1094 T1096 arg1Of Happold,al.
R652 T1094 T1097 arg1Of Happold,","
R653 T1098 T1097 arg2Of 2012,","
R654 T1100 T1101 arg1Of Johannessen,and
R655 T1101 T1099 arg2Of and,;
R656 T1101 T1103 arg1Of and,","
R657 T1101 T1105 arg1Of and,;
R658 T1101 T1111 arg1Of and,;
R659 T1102 T1101 arg2Of Bjerkvig,and
R660 T1104 T1103 arg2Of 2012,","
R661 T1106 T1105 arg2Of Kitange,;
R662 T1106 T1107 arg1Of Kitange,et
R663 T1106 T1108 arg1Of Kitange,al.
R664 T1106 T1109 arg1Of Kitange,","
R665 T1110 T1109 arg2Of 2012,","
R666 T1112 T1111 arg2Of Kohsaka,;
R667 T1112 T1113 arg1Of Kohsaka,et
R668 T1112 T1114 arg1Of Kohsaka,al.
R669 T1112 T1115 arg1Of Kohsaka,","
R670 T1112 T1117 arg1Of Kohsaka,;
R671 T1116 T1115 arg2Of 2012,","
R672 T1118 T1117 arg2Of Zhang,;
R673 T1118 T1119 arg1Of Zhang,et
R674 T1118 T1120 arg1Of Zhang,al.
R675 T1118 T1121 arg1Of Zhang,","
R676 T1122 T1121 arg2Of 2012b,","
R677 T1123 T1087 arg3Of ),(